Product Pathways - Growth Factors/Cytokines
Human Interleukin-10 (hIL-10) #8903
|8903LF||50 µg (Carrier Free)||---||In Stock||---|
|8903LC||50 µg (With Carrier)||---||In Stock||---|
|8903SC||10 µg (With Carrier)||---||In Stock||---|
|8903SF||10 µg (Carrier Free)||---||In Stock||---|
Already purchased this product? Write a Review.
Recombinant human IL-10 (hIL-10) Ser19 - Asn178 (Accession # NM_000572) was produced in E. coli at Cell Signaling Technology.
Recombinant hIL-10 does not have a Met on the amino terminus and has a calculated MW of 18,647. DTT-reduced protein migrates as an 18 kDa polypeptide and non-reduced protein migrates as a 16 kDa polypeptide due to intramolecular cystines. The expected amino-terminal SPGQG of recombinant hIL-10 was verified by amino acid sequencing.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIL-10. All lots are greater than 98% pure.
The bioactivity of recombinant hIL-10 was determined in a MC/9 cell proliferation assay. The ED50 of each lot is between 0.3-1.3 ng/ml.
The purity of recombinant hIL-10 was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hIL-10 and staining overnight with Coomassie Blue.
The proliferation of MC/9 cells treated with increasing concentrations of hIL-10 in the presence of 10 pg/ml mouse IL-4 was assessed. After 72 hours treatment with hIL-10, cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.
Western blot analysis of extracts from MC/9 cells, untreated or treated with hIL-10 for 20 minutes, using Phospho-Stat3 (Tyr705) (D3A7) Rabbit mAb #9145 (upper) or Stat3 Antibody #9132 (lower).
Less than 0.01 ng endotoxin/1μg hIL-10.
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hIL-10. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.
IL-10 is an anti-inflammatory cytokine that is produced by T cells, NK cells and macrophages (1,2). IL-10 initiates signal transduction by binding to a cell surface receptor complex consisting of IL-10 RI and IL-10 RII (1). Binding of IL-10 leads to the activation of Jak1 and Tyk2, which phosphorylates Stat-3 (1,3). The anti-inflammatory activity of IL-10 is due to its ability to block signaling through other cytokine receptors, notably IFNγ receptor, by upregulating expression of SOCS-1 (1,3). In addition, IL-10 promotes T cell tolerance by inhibiting tyrosine phosphorylation of CD28 (4,5). IL-10 is an important negative regulator of the immune response, which allows for maintenance of pregnancy (1). In contrast, increased IL-10 levels contribute to persistent Leishmania major infections (6).
- Pestka, S. et al. (2004) Immunol Rev 202, 8-32.
- Akuffo, H. et al. (1999) Clin Exp Immunol 117, 529-34.
- O'Shea, J.J. and Murray, P.J. (2008) Immunity 28, 477-87.
- Akdis, C.A. and Blaser, K. (2001) Immunology 103, 131-6.
- Akdis, C.A. et al. (2000) FASEB J 14, 1666-8.
- Von Stebut, E. (2000) Eur J Dermatol 17, 115-22.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.